Abstract Background Rapid molecular testing is crucial in pediatric care for the timely detection of respiratory viruses. Our aim was to determine the impact of a testing algorithm by comparing single-plex assays - ID NOW™ INFLUENZA A viral positivity ranged from 25% to 63%. During peak testing, median TATs were 19 minutes, 20 minutes and 39 minutes reported for Abbott Flu A/B, Abbott RSV and FLUVID assays, respectively (Table 1). All 3 assays showed 90% test completion within a 60-minute metric at the Emergency Department (ED) setting; however, FLUVID failed 8.5% of the times in the Urgent Care (UC). High positivity ( 46%) was reported with single-plex testing for Flu A and RSV across all age groups (Table 2). However, positivity was lower when physicians offered FLUVID or simultaneous testing for Flu A/B and RSV by Abbott (Table 2). Overall, LOS was shorter both in the ED and UC with FLUVID (Table 3). Higher proportion of children with Abbott Flu A/B tests (12.2%) received Baloxavir compared to those with FLUVID (5.2%). Conclusion Our testing algorithm with a combination of single-plex and 4plex assays showed shorter TAT with Abbott but longer LOS with FLUVID. Providers opted for both types of tests when given a chance and reported higher positivity with Abbott assays. Age-appropriate children with Abbott Flu results received higher rate of Baloxavir at the time of discharge. However, all results may have been impacted by staffing, number of modules, and volume of testing and may account for the differences at each location. Disclosures Brian R. Lee, PhD, MPH, Merck: Grant/Research Support Rangaraj Selvarangan, PhD, Altona: Grant/Research Support|Biomerieux: Advisor/Consultant|Biomerieux: Grant/Research Support|Biomerieux: Honoraria|Cepheid: Grant/Research Support|Hologic: Grant/Research Support|Hologic: Honoraria|Meridian: Grant/Research Support|Qiagen: Grant/Research Support
Bartlett et al. (Thu,) studied this question.